[HTML][HTML] Mini-organs with big impact: Organoids in liver cancer studies
Hepatocellular carcinoma, the most common primary liver cancer and a leading cause of
death, is a difficult disease to treat due to its heterogeneous nature. Traditional models, such …
death, is a difficult disease to treat due to its heterogeneous nature. Traditional models, such …
[HTML][HTML] A narrative review of supportive and end of life care considerations in advanced hepatocellular carcinoma
IN Hashmi, HM Lee, JP Wedd… - Annals of Palliative …, 2023 - apm.amegroups.org
Methods: A search of PubMed was conducted from inception of the database to March 1,
2023. The search was composed of keywords and controlled vocabulary terms for concepts …
2023. The search was composed of keywords and controlled vocabulary terms for concepts …
Cancer stigma: the need for policy and programmatic action
SE Johnson, M Samson - JNCI Monographs, 2024 - academic.oup.com
Cancer is a stigmatized disease in many countries that impacts the quality of life and mental
health of people affected by cancer. This commentary examines some dimensions of cancer …
health of people affected by cancer. This commentary examines some dimensions of cancer …
Tislelizumab vs sorafenib in first-line treatment of unresectable hepatocellular carcinoma: impact on health-related quality of life in RATIONALE-301 study
RS Finn, M Kudo, G Barnes, T Meyer, F Boisserie… - Liver Cancer, 2024 - karger.com
Abstract Introduction: RATIONALE-301 (NCT03412773) was a global, phase 3 study
comparing the efficacy and safety of tislelizumab with sorafenib as first-line (1L) treatment in …
comparing the efficacy and safety of tislelizumab with sorafenib as first-line (1L) treatment in …
Global status of research on gastrointestinal cancer patients' quality of life: A bibliometric and visual analysis from 2003 to 2023
X Wang, C Wang, W Han, J Sun, Z Hui, S Lei, H Wu… - Heliyon, 2024 - cell.com
Objective To analyze the current research status, hotspots, and frontiers in the field of
Gastrointestinal (GI) cancer and quality of life (QoL) through the bibliometrics method, and to …
Gastrointestinal (GI) cancer and quality of life (QoL) through the bibliometrics method, and to …
Stigmatization of drinking patients with liver cancer: The role of socioeconomic status
C Auriol, P Raynal, N Cantisano - Heliyon, 2024 - cell.com
Patients with liver cancer may face stigmatization due to cancer, alcohol consumption, or
both. This study addresses gaps in the existing literature regarding stigmatization of alcohol …
both. This study addresses gaps in the existing literature regarding stigmatization of alcohol …
An offline to online cognitive behavioral stress management caring program effectively improves psychological pressure, spiritual well-being, and quality of life in …
Y Liu, M Sun - Clinics and Research in Hepatology and …, 2023 - Elsevier
Background This study designed an offline to online cognitive behavioral stress
management (OOsingle bondCBSM) caring program, intending to investigate its effect on …
management (OOsingle bondCBSM) caring program, intending to investigate its effect on …
Effect of multi-disciplinary team care program on quality of life, anxiety, and depression in hepatocellular carcinoma patients after surgery: a randomized, controlled …
L Yang, C Yan, J Wang - Frontiers in Surgery, 2023 - frontiersin.org
Objective Multi-disciplinary team (MDT) collaboration enables hepatocellular carcinoma
(HCC) patients to achieve better survival through precise diagnosis and individualized …
(HCC) patients to achieve better survival through precise diagnosis and individualized …
Tislelizumab versus Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma: Impact on Health-Related Quality of Life in RATIONALE-301 Study
RSFMK Gisoo, BT Meyerd, FBRAY Cheng, S Lih… - chemotherapy, 2024 - karger.com
Abstract Introduction: RATIONALE-301 (NCT03412773) was a global, phase 3 study
comparing the efficacy and safety of tislelizumab with sorafenib as first-line (1L) treatment in …
comparing the efficacy and safety of tislelizumab with sorafenib as first-line (1L) treatment in …
卡瑞利珠单抗联合阿帕替尼对晚期肝癌患者健康相关生活质量的影响
汪蕊， 陈宇佛， 张甜甜， 刘杨， 张珊珊， 李玉梅 - 中华全科医学, 2023 - zhqkyx.net
目的分析卡瑞利珠单抗联合阿帕替尼在晚期肝癌(HCC) 一线治疗中的疗效及对患者生活质量的
影响. 方法收集2020 年1 月—2022 年6 月在蚌埠医学院第一附属医院接受卡瑞利珠单抗联合阿 …
影响. 方法收集2020 年1 月—2022 年6 月在蚌埠医学院第一附属医院接受卡瑞利珠单抗联合阿 …